This clinical trial focuses on patients with Crohn’s disease, a condition that causes inflammation in the digestive tract. The study aims to prevent the return of the disease after surgery, specifically after a procedure called an ileocolonic resection, where part of the intestine is removed and reconnected. The trial will compare two approaches to starting treatment with biological medications. Biological medications are treatments made from living organisms or their products and are used to reduce inflammation and prevent disease recurrence.
The medications being studied include Risankizumab, Infliximab, Adalimumab, Ustekinumab, and Vedolizumab. These medications are given as injections or infusions, which means they are administered directly into the body through a needle. The study will compare starting these medications immediately after surgery to starting them only if the disease returns, as seen through an endoscopy, a procedure that uses a camera to look inside the digestive tract.
The purpose of the study is to determine which approach is more effective in preventing the return of Crohn’s disease after surgery. Participants will be randomly assigned to one of the two treatment groups and will be monitored over a period of time to assess the recurrence of the disease and any side effects from the medications. The study will help to understand the best timing for starting biological therapy to improve outcomes for patients with Crohn’s disease after surgery.
Belgium 
Italy 
